BioMarin Pioneer Honored through New Building Name and Book Launch
“BioMarin stands on the precipice of a gene therapy revolution, and this is a dream come true,” said Robert A. Baffi, Ph.D., retired president of Global Manufacturing and Technical Operations, at a ceremony announcing the renaming of our gene therapy manufacturing facility in his honor and the launch of his new book on how to achieve manufacturing success.
The new building name—Robert A. Baffi Gene Therapy Manufacturing Facility—commemorates more than two decades of extraordinary contributions by Dr. Baffi before his retirement from BioMarin in 2020. A visionary leader for our Technical Operations organization and company more broadly, Dr. Baffi guided BioMarin through many of the most important advances in our 25-year history, from expanding our state-of-the-art core facilities in Novato, to purchasing our Shanbally facility in Ireland, to turning a Novato office building into a full cGMP (current Good Manufacturing Practices) gene therapy manufacturing facility
“In addition to our patients, Robert has impacted the people at BioMarin as a mentor, a colleague and a friend,” Chairman and Chief Executive Officer JJ Bienaimé said at the naming celebration, where he also announced the launch of Dr. Baffi’s new book, “Making a Habit of Quality: How Technical Operations Paved the Way for BioMarin’s Success.”
In the book, Dr. Baffi details the critical role of the Technical Operations organization in BioMarin’s evolution—growing from a start-up with one groundbreaking rare disease therapy to a world leader in transforming lives through genetic discovery. With his willingness to take calculated risks, passion for innovation and commitment to patients, Dr. Baffi shares the story of how his leadership style helped to inspire the “TOPS” team to constantly reach for more, in service of the people who depend on our pioneering treatments around the world.
“I appreciate you all,” Dr. Baffi said to the many colleagues in attendance at the ceremony. “I’m immensely proud to have worked with you to achieve some awesome accomplishments, and, quite frankly, I enjoyed the hell out of every minute of it.”
Read the book “Making a Habit of Quality: How Technical Operations Paved the Way for BioMarin’s Success,” on our website by clicking here.
More from BioMarin
For geneticist Daniel Gaffney, becoming an expert in how genes influence human health was not enough. His drive to improve lives with this knowledge led him to BioMarin, where he found a shared commitment to translating scientific advances into medicines that solve genetic problems. Since joining the company earlier this year, Dan has helped its […]
After growing up with a brother living with hemophilia A and working in roles supporting the bleeding disorder community for years, Jess Klass thought she knew everything there was to know about hemophilia.
We’re thrilled to share that the U.S. Food and Drug Administration has approved our gene therapy for a genetic bleeding disorder. Developing the one-time therapy and bringing it over the finish line, first in Europe and now the United States, has been a global effort. Our teams have made unprecedented scientific, medical, manufacturing and regulatory […]